 |
|
SATURDAYOctober 16SESSION 32:00– 2:15Click here to return to Dermatology Update 2004 Schedule and Abstracts |
Greg Hines The mapping of the Human Genome has spurred research programs related to the discovery of new therapeutic agents, disease diagnostic applications and a variety of agricultural and veterinary applications. Unfortunately, the public expectation for significant improvements to human healthcare has not been fulfilled. Tm Bioscience Corporation is a biotechnology company involved in the development and commercialization of a variety of genetic tests for the detection of genetic mutations related to the diagnosis of or predisposition to disease in patients. The company employs a microarray technology platform capable of testing for more than 1000 genetic mutations in a single drop of blood. The platform provides clinical laboratories with a system capable of evaluating thousands of patient samples per day at a cost that is less than $50.00 per patient report. This presentation will address three areas that DNA testing might soon affect the Dermatologist. These include Melanoma, Damaged Skin and Drug Therapy. The company has developed in conjunction with Dr. David Hogg U. of T. a screen for the selection of patients predisposed to melanoma. During the presentation, you will learn how this test might affect the way you screen and manage your patients. An examination of mitochondrial DNA can be a valuable tool for the identification of the health of the metabolic processes within a given cell. Researchers at Genesis Genomics Inc. have identified genetic markers within the mitochondrial DNA that indicate the degree of damage to keratinocytes. The third topic for presentation will be the role of DNA testing in the determination of patient risk prior to the selection of a drug. A specific focus will be on the genetic tests that are currently marketed for this purpose.
Click here to return to Dermatology Update 2004 Schedule and Abstracts |